A Wakui

1.8k total citations
107 papers, 1.5k citations indexed

About

A Wakui is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, A Wakui has authored 107 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 42 papers in Molecular Biology and 31 papers in Cancer Research. Recurrent topics in A Wakui's work include Cancer, Hypoxia, and Metabolism (22 papers), Cancer Treatment and Pharmacology (22 papers) and Cancer therapeutics and mechanisms (17 papers). A Wakui is often cited by papers focused on Cancer, Hypoxia, and Metabolism (22 papers), Cancer Treatment and Pharmacology (22 papers) and Cancer therapeutics and mechanisms (17 papers). A Wakui collaborates with scholars based in Japan, United States and Canada. A Wakui's co-authors include I Nakao, K Futatsuki, Y. Shimada, Ryunosuke Kanamaru, Makoto Yoshino, Tetsuya Taguchi, N. Ogawa, Yasushi Sakata, T Taguchi and Chikashi Ishioka and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Biochemical and Biophysical Research Communications.

In The Last Decade

A Wakui

98 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A Wakui Japan 16 719 708 371 245 202 107 1.5k
Tina Colombo Italy 25 737 1.0× 910 1.3× 295 0.8× 102 0.4× 242 1.2× 76 1.8k
P J O'Dwyer United States 23 1.1k 1.5× 998 1.4× 332 0.9× 440 1.8× 351 1.7× 50 2.3k
Colin Paul Spears United States 22 600 0.8× 871 1.2× 292 0.8× 213 0.9× 262 1.3× 53 1.5k
P. A. Philip United States 21 601 0.8× 800 1.1× 436 1.2× 261 1.1× 391 1.9× 81 1.5k
G G Chabot France 15 915 1.3× 1.0k 1.4× 169 0.5× 115 0.5× 92 0.5× 24 1.4k
H J Broxterman Netherlands 21 1.2k 1.7× 1.7k 2.4× 185 0.5× 269 1.1× 214 1.1× 27 2.4k
Bach Ardalan United States 22 601 0.8× 1.1k 1.6× 453 1.2× 311 1.3× 174 0.9× 105 1.9k
Mingxin Che United States 25 703 1.0× 582 0.8× 457 1.2× 255 1.0× 440 2.2× 36 1.9k
J van Ark-Otte Netherlands 17 754 1.0× 710 1.0× 249 0.7× 190 0.8× 132 0.7× 25 1.3k
Takafumi Nishimura Japan 21 823 1.1× 639 0.9× 269 0.7× 197 0.8× 286 1.4× 51 1.8k

Countries citing papers authored by A Wakui

Since Specialization
Citations

This map shows the geographic impact of A Wakui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Wakui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Wakui more than expected).

Fields of papers citing papers by A Wakui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A Wakui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Wakui. The network helps show where A Wakui may publish in the future.

Co-authorship network of co-authors of A Wakui

This figure shows the co-authorship network connecting the top 25 collaborators of A Wakui. A scholar is included among the top collaborators of A Wakui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A Wakui. A Wakui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kurihara, Minoru, N Horikoshi, Nobuteru Kikkawa, et al.. (1999). Phase II study of raltitrexed (Tomudex®) in chemotherapy-pretreated patients with advanced colorectal cancer. Anti-Cancer Drugs. 10(8). 741–748. 9 indexed citations
2.
Kikuchi, Hiroaki, et al.. (1997). Features of DNA Oligonucleosomal Fragmentation in Human Tumor Cell Lines and Its Detection by Flow Cytometry: Utility and Limitations. Japanese Journal of Cancer Research. 88(1). 56–63. 8 indexed citations
3.
Itoh, Yumi, et al.. (1995). Zinc distribution in malignant tumors. 6(1). 45–50. 3 indexed citations
4.
Yoshida, Takashi, Kazuo Ota, Yutaka Yoshida, et al.. (1993). Phase II study of NK313 in malignant lymphomas: an NK313 Malignant Lymphoma Study Group trial. Cancer Chemotherapy and Pharmacology. 31(6). 445–448. 1 indexed citations
5.
Imaizumi, Munehisa, Tatsuhei Kondo, T Taguchi, et al.. (1993). A standardized method of using nude mice for the in vivo screening of antitumor drugs for human tumors. Surgery Today. 23(5). 412–419. 8 indexed citations
6.
Uematsu, Fumiyuki, Hideaki Kikuchi, Masakichi Motomiya, et al.. (1991). Association between Restriction Fragment Length Polymorphism of the Human Cytochrome P450IIE1 Gene and Susceptibility to Lung Cancer. Japanese Journal of Cancer Research. 82(3). 254–256. 184 indexed citations
7.
Yoshioka, Takuyuki, Hiroyuki Takahashi, Sakan Maeda, et al.. (1990). 18FDG Uptake of Human Cancers Heterotransplanted into Nude Mice-Comparison with the Degree of the Histological Differentiation. 1990(1990). 135–141.
8.
Taguchi, T, et al.. (1990). [Phase I clinical study of CPT-11. Research group of CPT-11].. PubMed. 17(1). 115–20. 58 indexed citations
9.
Shibata, Hiroyuki, Ryunosuke Kanamaru, Toshiaki Sato, et al.. (1990). Increase in the Level of P‐Glycoprotein mRNA Expression in Multidrug‐resistant K562 Cell Lines Treated with Sodium Butyrate Is Not Accompanied with Erythroid Differentiation. Japanese Journal of Cancer Research. 81(12). 1214–1217. 11 indexed citations
10.
Sato, Haruhiko, et al.. (1989). Angiotensin II induced hypertension chemotherapy(IHC) and dose intensity(DL).. Drug Delivery System. 4(2). 105–110. 1 indexed citations
11.
Kanamaru, Ryunosuke, et al.. (1989). Mechanism of action of the synthetic imidazole compound YM 534 on human promyelocytic leukemia line HL-60 cells.. PubMed. 4(2). 137–44. 1 indexed citations
12.
Ishioka, Chikashi, et al.. (1988). Inhibitory effects of prostaglandin A2 on c-myc expression and cell cycle progression in human leukemia cell line HL-60.. PubMed. 48(10). 2813–8. 42 indexed citations
13.
Kanamaru, Ryunosuke, et al.. (1988). The mechanism of action of quinocarmycin citrate (KW 2152) on mouse L1210 cells in vitro. Cancer Chemotherapy and Pharmacology. 22(3). 197–200. 14 indexed citations
14.
Taguchi, T., et al.. (1987). [A model for the sensitivity determination of anticancer agents against human cancer using nude mice].. PubMed. 14(3 Pt 1). 680–6. 9 indexed citations
15.
Kimura, Kiyoji, T Taguchi, I Urushizaki, et al.. (1987). Phase I study of recombinant human tumor necrosis factor. Cancer Chemotherapy and Pharmacology. 20(3). 223–229. 110 indexed citations
16.
Takahashi, Hiroko, Shin Maeda, A Wakui, et al.. (1986). Changes in Growth and 18FDG(2-Deoxy-2-[18F]Fluoro-D-Glucose) Uptake of Rat Hepatomas by Anticancer Drugs. 1986(1986). 195–200. 4 indexed citations
17.
Takahashi, Hiroko, A Wakui, Shin Maeda, et al.. (1985). Changes of 2-Deoxy-2-Fluoro-[18F]-D-Glucose Uptake tn Rat Hepatomas by Anticancer Drugs. 1985. 144–149. 1 indexed citations
18.
Takahashi, Hidenobu, et al.. (1984). Studies on Myocardial Glucose Metaboltsm of Adriamycin-Administered Rats Using Positron-Emitting Radiopharmaceuticals. 1984(1984). 220–226. 1 indexed citations
19.
Wakui, A, et al.. (1977). Combination chemotherapy for solid tumors using 5-fluorouracil, chromomycin-A, and prednisolone.. PubMed. 68(4). 375–87. 1 indexed citations
20.
Wakui, A, et al.. (1959). Diets and Progress of Alloxan Diabetes. The Tohoku Journal of Experimental Medicine. 69(4). 307–317. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026